10 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·1 day ago, 12:35 PMCNC-0.89%AMGN-1.05%
Does ImmunityBio’s (IBRX) Jim Yong Kim Hire Transform Its Global Access Strategy For Immunotherapies?Simplywall·Aug 24 at 04:25 PMIBRX-4.17%
Weekly Recap | ImmunityBio this week, a quiet, low-volume weekWeekly Review·Aug 22 at 12:07 AMIBRX-4.17%
147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.Market Beat·Aug 15 at 05:49 AMIBRX-4.17%
ImmunityBio names former World Bank chief Jim Yong Kim vice chairmanPUBT·Aug 10 at 08:03 AMIBRX-4.17%
ImmunityBio: ANKTIVA’s Sustained Growth and Regulatory Catalysts Support Reaffirmed Buy Rating and Unchanged $15 Price TargetTip Ranks·Aug 4 at 01:05 PMIBRX-4.17%
ImmunityBio posts Q2 2026 product revenue $50.7M; H1 revenue $94.8M, cash $357.4MTradingView·Aug 4 at 06:43 AMIBRX-4.17%
ImmunityBio Q2 FY26 net loss widens to $230.4 million; revenue rises 92% YoY to $50.7 millionPUBT·Aug 4 at 06:35 AMIBRX-4.17%
Arete Wealth Advisors LLC Makes New Investment in ImmunityBio, Inc. $IBRXMarket Beat·Aug 1 at 02:14 AMIBRX-4.17%
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drugbenzinga_article·Jul 30 at 12:20 PMIBRX-4.17%
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer | IBRX Stock NewsStockTitan·Jul 29 at 09:45 AMIBRX-4.17%
Are Surging IBRX Retail Debates Hinting at a Deeper Re‑rating of ImmunityBio’s Platform?Simplywall·Jul 15 at 04:13 AMIBRX-4.17%
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Nowbenzinga_article·Jul 13 at 01:29 PMSOUN-1.52%FLNC-4.81%
